Skip to main content
. 2026 Jul 20;17:1855538. doi: 10.3389/fimmu.2026.1855538

Figure 4.

Three scatter dot plots with error bars display serum ADA levels in different groups. Panel A compares ADA across anatomical patterns AU, IU, PU, and PAN, showing significant differences indicated by asterisks. Panel B compares ADA based on anterior chamber cell scores (ACC 0+ vs ACC ≥0.5+), and Panel C compares ADA by vitreous haze scores (VH 0+ vs VH ≥0.5+), both with significant differences marked by three asterisks.

Association between inflammatory parameters and serum adalimumab levels in non-infectious uveitis. Serum trough levels of adalimumab (ADA) according to inflammatory disease characteristics in patients with non-infectious uveitis. (A) ADA levels according to anatomical classification of uveitis (anterior uveitis [AU], intermediate uveitis [IU], posterior uveitis [PU], and panuveitis [PAN]). (B) ADA levels according to anterior chamber cell grade based on the Standardization of Uveitis Nomenclature (SUN) criteria (0 vs ≥0.5+). (C) ADA levels according to vitreous haze grade based on the National Eye Institute (NEI) scale (0 vs ≥0.5+). Each dot represents an individual measurement (n = 135). Horizontal lines indicate median values with interquartile range (IQR). Statistical analyses were performed using the Mann–Whitney U test or Kruskal–Wallis test, as appropriate, followed by post hoc pairwise comparisons when applicable. *p < 0.05, **p < 0.01, ***p < 0.001.